Efficacy of Interferon-β in Moderate-to-Severe Hospitalised Cases of COVID-19: A Systematic Review and Meta-analysis.

Subodh KumarManoj Kumar SaurabhVenkata Lakshmi NarasimhaVikas Maharshi

Published in: Clinical drug investigation (2021)

Addition of interferon-β to standard of care resulted in significant reduction in time to clinical improvement but no significant benefit in terms of reduction in mortality and length of hospital stay in moderate-to-severe cases of COVID-19.

Keyphrases

coronavirus disease
sars cov
healthcare
dendritic cells
high intensity
early onset
palliative care
cardiovascular events
respiratory syndrome coronavirus
quality improvement
emergency department
cardiovascular disease
immune response
pain management
acute care
chronic pain
health insurance